Abstract
AimDupilumab, a fully human monoclonal antibody, blocks the shared receptor component for IL-4/13, key and central drivers of type 2 (T2) inflammation. Dupilumab had an acceptable safety profile and showed...
Full Text 
Sign-in/Register to access full text options
Sign-in/Register to access full text options 
Paper version not known
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call
